Biotech: Eye-to-eye with a pandemic - Managing the reality and challenges of COVID-19
The arrival of COVID-19 earlier this year thrust the world into a new era of crisis. The global pandemic had an immediate impact on traditional business cycles and normal operating environments, engendering a prolonged anxiety of what the future may look like.
Amid these challenges arose a widespread belief that disruption can spark constructive change, and from that change could bring growth.
Through this whitepaper, Samsung Biologics outlines the areas that were critical in adapting best practices for business management in dealing with the pandemic including employee safety, GMP compliance, supply chain management, and digital adaptation.
The arrival of COVID-19 earlier this year thrust the world into a new era of crisis. The global pandemic had an immediate impact on traditional business cycles and normal operating environments, engendering a prolonged anxiety of what the future may look like.
Amid these challenges arose a widespread belief that disruption can spark constructive change, and from that change could bring growth.
Through this whitepaper, Samsung Biologics outlines the areas that were critical in adapting best practices for business management in dealing with the pandemic including employee safety, GMP compliance, supply chain management, and digital adaptation.
- CDO
- CGMP
- ADC
- Bio Campus
- IR
- CMO